Story

Mineralys Therapeutics Stock Slides on Wider-Than-Expected Loss, Surging R&D Costs

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Mineralys Therapeutics Stock Slides on Wider-Than-Expected Loss, Surging R&D Costs
Text size
Background

Mineralys Therapeutics (NASDAQ: MLYS) saw its shares fall in after-hours trading after the company reported a second-quarter loss that was wider than Wall Street expectations, fueled by a sharp increase in operating expenses as it prepares for the potential commercial launch of its lead drug candidate.

The stock dropped 4.9% in the post-market session. The move was company-specific, as major U.S. indices like the S&P 500 and Nasdaq finished the regular trading day relatively unchanged.

Earnings Driven by Strategic Spending

The biopharmaceutical firm posted a net loss of $2.85 per share for the second quarter, missing the analyst consensus estimate of a $2.63 per-share loss. The result also marked a significant deterioration from the 47-cent loss reported in the first quarter, according to the company's release.

The earnings miss was primarily caused by a surge in operating costs as the company invests in its pipeline:

Sample IUX Markets – In-articleAd
  • Research and development (R&D) expenses ballooned to $221.4 million, a substantial increase from $38.3 million in the same period a year earlier.
  • The company attributed the majority of this increase to a $200 million upfront payment made to Tanabe in June 2026 to acquire future royalty obligations for its hypertension drug, lorundrostat.
  • General and administrative expenses also climbed to $24.7 million from $8.5 million year-over-year, reflecting the ramp-up of commercialization activities.

Focus Shifts to FDA Decision

Despite the market's reaction to the quarterly loss, Mineralys is approaching a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026, for its decision on lorundrostat.

CEO Jon Congleton noted that commercial preparations for the potential launch remain on track. The company also reported a solid cash position, which it stated is sufficient to support operations into 2028, providing a financial runway as it awaits the FDA's decision.

Read next

More on Stocks
Back to latest news

LATEST